JP2022524958A5 - - Google Patents
Info
- Publication number
- JP2022524958A5 JP2022524958A5 JP2021550221A JP2021550221A JP2022524958A5 JP 2022524958 A5 JP2022524958 A5 JP 2022524958A5 JP 2021550221 A JP2021550221 A JP 2021550221A JP 2021550221 A JP2021550221 A JP 2021550221A JP 2022524958 A5 JP2022524958 A5 JP 2022524958A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tcr
- antibody
- immune cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821768P | 2019-03-21 | 2019-03-21 | |
| US62/821,768 | 2019-03-21 | ||
| PCT/US2020/024059 WO2020191378A1 (en) | 2019-03-21 | 2020-03-20 | METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524958A JP2022524958A (ja) | 2022-05-11 |
| JP2022524958A5 true JP2022524958A5 (https=) | 2023-03-24 |
| JP7638881B2 JP7638881B2 (ja) | 2025-03-04 |
Family
ID=70296049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550221A Active JP7638881B2 (ja) | 2019-03-21 | 2020-03-20 | ＴＣＲαβ＋細胞の枯渇効率を向上させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200317780A1 (https=) |
| EP (1) | EP3941488B1 (https=) |
| JP (1) | JP7638881B2 (https=) |
| KR (1) | KR102942960B1 (https=) |
| CN (1) | CN113490502A (https=) |
| BR (1) | BR112021018684A2 (https=) |
| CA (1) | CA3130701A1 (https=) |
| ES (1) | ES3036043T3 (https=) |
| IL (1) | IL286909B2 (https=) |
| MX (1) | MX2021010998A (https=) |
| WO (1) | WO2020191378A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022132720A1 (en) * | 2020-12-14 | 2022-06-23 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
| EP4353253A1 (en) | 2022-10-10 | 2024-04-17 | Charité - Universitätsmedizin Berlin | Purification of tcr-modified t cells using tcr-specific car-nk cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| AU2015214145A1 (en) | 2014-02-04 | 2016-08-25 | Kite Pharma. Inc. | Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| CN107828730B (zh) * | 2017-11-07 | 2019-04-30 | 南京北恒生物科技有限公司 | 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法 |
-
2020
- 2020-03-20 WO PCT/US2020/024059 patent/WO2020191378A1/en not_active Ceased
- 2020-03-20 US US16/826,102 patent/US20200317780A1/en active Pending
- 2020-03-20 KR KR1020217028506A patent/KR102942960B1/ko active Active
- 2020-03-20 JP JP2021550221A patent/JP7638881B2/ja active Active
- 2020-03-20 MX MX2021010998A patent/MX2021010998A/es unknown
- 2020-03-20 ES ES20720187T patent/ES3036043T3/es active Active
- 2020-03-20 CN CN202080018210.7A patent/CN113490502A/zh active Pending
- 2020-03-20 BR BR112021018684A patent/BR112021018684A2/pt unknown
- 2020-03-20 IL IL286909A patent/IL286909B2/en unknown
- 2020-03-20 CA CA3130701A patent/CA3130701A1/en active Pending
- 2020-03-20 EP EP20720187.2A patent/EP3941488B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease | |
| Withers et al. | Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program | |
| Aqmasheh et al. | Effects of mesenchymal stem cell derivatives on hematopoiesis and hematopoietic stem cells | |
| Pira et al. | Selective depletion of αβ T cells and B cells for human leukocyte antigen–haploidentical hematopoietic stem cell transplantation. A three-year follow-up of procedure efficiency | |
| EP3219790B1 (en) | Myocardial cell sheet | |
| JP2016509840A5 (https=) | ||
| JP2012521215A5 (https=) | ||
| JP2017524031A (ja) | ガンマデルタｔ細胞およびその使用 | |
| Fang et al. | Technical advances in NK cell-based cellular immunotherapy | |
| JP2022524958A5 (https=) | ||
| CN102027104A (zh) | 含有细胞因子诱导杀伤细胞的细胞群的制造方法 | |
| CN107002036A (zh) | 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法 | |
| CN119698465A (zh) | 快速t细胞制造 | |
| O’Neal et al. | Traversing the bench to bedside journey for iNKT cell therapies | |
| CN114040967A (zh) | 造血干细胞移植后恢复及促进恢复的改进 | |
| Stevanović et al. | Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia | |
| JP2022023136A5 (https=) | ||
| Gao et al. | Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease | |
| Takahashi et al. | T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy | |
| JPWO2009145238A1 (ja) | 免疫調節剤及びその利用 | |
| JP2024538258A5 (https=) | ||
| JP2019534684A (ja) | 細胞を活性化させるための方法およびキット | |
| Lee et al. | A strategy for enhancing the engraftment of human hematopoietic stem cells in NOD/SCID mice | |
| JP7638881B2 (ja) | ＴＣＲαβ＋細胞の枯渇効率を向上させる方法 | |
| Mukhametshin et al. | Allogeneic NKG2D CAR-T Cell Therapy: A Promising Approach for Treating Solid Tumors |